The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 358:1072-1073 March 6, 2008 Number 10
NextNext

Eltrombopag in Thrombocytopenia

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by McHutchison, J. G.
-Related Article
by Bussel, J. B.
-PubMed Citation
To the Editor: McHutchison et al. (Nov. 29 issue)1 report that eltrombopag (a thrombopoietin-receptor agonist) raises the platelet count in patients with hepatitis C cirrhosis and thrombocytopenia. Its application in treating interferon-induced thrombocytopenia, however, necessitates that it improve the sustained virologic response. Even among patients with cirrhosis, thrombocytopenia leads to discontinuation of treatment in only 2% of patients.2 Of interest, therefore, is the question of whether eltrombopag prevents the reduction in the dose of interferon that partially explains the poor sustained virologic response in cirrhosis.3 McHutchison et al. state that in their study, platelet counts remained higher than the level . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.